News & Media
SK life science
Welcome to the news and information center for SK Life Science, Inc. (SKLSI), a CNS-focused pharmaceutical company
Here you will find the latest announcements and contact information for SK life science.
For media inquiries, please contact Media@SKLSI.com.
General business
Strategic alliance and partnership opportunities
Media inquiries and PR
Grant and investigator initiated proposals
Sponsorship requests
Medical information inquiries or report adverse events
1-866-OKSKLSI (657-5574)
medicalinfo@sklsi.com
SK life science at a glance
-
Headquarters location
PARAMUS, NJ
-
R&D Begins
1993
-
Parent Company
SK life science is a subsidiary of SK Biopharmaceuticals, Co., Ltd., and both are part of the SK Group
-
Number of employees
200+ EMPLOYEES
-
Disease Category Focus
CNS
-
Pipeline
8 compounds under clinical development
Newsroom
1/29/2021
Cenobamate Receives Positive CHMP Opinion for Adjunctive Treatment of Focal-Onset (Partial-Onset) Seizures
Full release1/04/2021
SK Biopharmaceuticals To Sell Arvelle Therapeutics Stake As Part Of Angelini Pharma’s Acquisition Of Arvelle Therapeutics
Full release12/01/2020
SK life science Presents Latest Cenobamate Data at the American Epilepsy Society AES2020 Virtual Event
Full release10/29/2020
SK Biopharmaceuticals and LifeSci Venture Partners Forge Ties for Open Innovation
Full release10/13/2020
SK Biopharmaceuticals, Ono Pharmaceutical Enter Licensing Agreement for Cenobamate in Japan
Full release9/11/2020
SK Biopharmaceuticals Initiates Clinical Development Program for Cenobamate in Asia
Full release7/15/2020
SK life science Expands Support for the Epilepsy Foundation to Advance Epilepsy Awareness, Research, Education and Care
Full release5/20/2020
Newly Published Study in Neurology Shows Cenobamate Significantly Reduced Seizure Frequency in Adults with Uncontrolled Partial-Onset (Focal) Seizures
Full release5/20/2020
SK life science Announces Results of Large, Open-Label Safety Study of Cenobamate Published in Epilepsia
Full release5/11/2020
SK life science Announces U.S. Availability of XCOPRI® (cenobamate tablets) CV for the Treatment of Partial-Onset Seizures in Adults
Full release5/05/2020
SK Life Science, Inc.’s Coronavirus Update
Full release3/26/2020
European Medicines Agency Accepts Arvelle Therapeutics’ Marketing Authorization Application for Cenobamate for the Adjunctive Treatment of Focal-Onset Seizures in Adults
Full release3/10/2020
SK life science Receives Schedule V Designation from DEA for XCOPRI® (cenobamate tablets)
Full release12/06/2019
SK life science to Present Latest Cenobamate Data at the American Epilepsy Society 2019 Annual Meeting
Full release12/02/2019
SK Life Science, Inc. Announces FDA Acceptance of IND Application for Anti-Epileptic Drug Candidate SKL24741
Full release11/21/2019
FDA Approves XCOPRI® (cenobamate tablets), an Anti-Epileptic Drug (AED) from SK Biopharmaceuticals, Co., Ltd., and U.S. Subsidiary SK Life Science, Inc.
Full release11/13/2019
Results of a Randomized Study of the Safety and Efficacy of Cenobamate in Adults with Uncontrolled Focal Seizures Published in The Lancet Neurology
Full release11/01/2019
New National Epilepsy Survey Reveals Significant Disconnects on Important Issues Among Patients, Caregivers and Healthcare Professionals
Full release7/17/2019
SK life science Expands Support for the J. Kiffin Penry Epilepsy Education Programs to Reach More Healthcare Providers
Full release5/13/2019
SK life science Provides Update on Recent Company Milestones and Accomplishments
Full release5/03/2019
SK life science to Showcase Scientific Data at the 2019 American Academy of Neurology Annual Meeting
Full release2/15/2019
SK Biopharmaceuticals and Arvelle Therapeutics Announce Agreement to Develop and Commercialize Cenobamate in Europe
Full release2/04/2019
SK life science announces FDA acceptance of NDA submission for cenobamate, an investigational antiepileptic drug
Full release12/03/2018
SK life science presents new data on its lead investigational compound, cenobamate, at the American Epilepsy Society 2018 Annual Meeting
Full release11/01/2018
SK life science honors Epilepsy Awareness Month with support for patients, advocates, caregivers, and healthcare providers
Full release5/15/2018
SK life science awards educational grant to J. Kiffin Penry Epilepsy Education Programs in support of neurology residents and epilepsy fellows
Full release4/23/2018
SK life science presents data on the investigational antiepileptic drug, cenobamate, at the American Academy of Neurology Annual Meeting 2018
Full release3/06/2018
SK life science to present data on cenobamate, an investigational antiepileptic compound, at ASCPT 2018 Annual Meeting
Full release11/29/2017
SK life science launches new corporate presence, expanded commercial operations in the United States.
Full release